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Introduction
The proto-oncogene, Bcl-2, was originally identified at the chromosomal breakpoint in t (14;18) bearing follicular B cell lymphoma [1] . Bcl-2 is a 26 kDa membrane-bound protein that is present in several subcellular locations including the outer mitochondrial, outer nuclear, and endoplasmic reticulum membranes [2, 3] . Bcl-2 family members that favor cell death include those containing multiple BH domains (Bax, Bak and Bok), and those that contain only the BH3 sequence (Bad, Bik, Bid, Bmf, Nova and Hrk). Anti-apoptotic Bcl-2 proteins are, Bcl-2, as well as Bcl-xL, Mcl-1, A1 and Bcl-w [4] . Bcl-2 can protect a variety of cell types against stress-induced apoptosis, and it controls outer mitochondrial membrane permeability and the release of cytochrome C [5] [6] [7] . It is also reported to be involved in regulation of the cell cycle, cell differentiation, and gene expression [8] [9] [10] .
Little is known of the mechanisms regulating Bcl-2 expression. We previously reported that PLD can regulate Bcl-2 expression in stomach cancer cells [11] and that overexpression of PLD2 enables A20 murine B lymphoma cells to resist Fas-induced apoptosis by increasing Bcl-2 and Bcl-xL expression [12] .
Phospholipase D (PLD), a phospholipids phosphohydrolase, catalyzes the hydrolysis of phosphatidylcholine to phosphatidic acid (PA) and choline. While the generation of choline by PLD may have some second messenger functions, it is widely believed that PA is the most critical metabolite generated by PLD. PA can also be metabolically converted to diacylglycerol (DAG) and lyso-PA (LPA), both of which have second messenger roles that could contribute to the effects of PLD. PLD has two isoforms, PLD1 and PLD2, with significant differences in their regulation and subcellular distributions. PLD1 is present throughout the cell, particularly in Golgi, perinuclear, and heavy membrane fractions, in contrast PLD2 is localized almost exclusively in the plasma membrane of the light membrane "lipid raft" which cofractionates with caveolin [13] . PLD1 is activated by ARF-, Ral-, and Rho-family GTPases, and PKCα while PLD2 activity is elevated by fatty acids, but is unaffected by GTPases or PKCα [14] . PLD plays an important regulatory role in various cellular processes, including cell migration, receptor endocytosis, exocytosis, cytoskeletal reorganization and membrane trafficking [14] , cell proliferation [15] , the immune response [16] , differentiation, survival, and apoptosis [17] . Although PLDs act as important regulators in the signaling pathways involved in cell survival, the role of PLDs in these pathways is still not fully understood.
Rho family, Small GTP-binding proteins, including Rho, Cdc42, and Rac1, play an important role in cellular functions including the cell cycle, cell polarity, survival, and migration [18] . The GTP-binding form of Rho can interact with their specific effecters and activate a range of downstream targets. In particular, Rho and its downstream effectors, such as Rho-associated kinase (Rho kinase) are involved in reorganization of the actin cytoskeleton in processes such as smooth muscle constriction [19] . Rho GTPases control the activity of phospholipase D (PLD) [20] and Rho-kinase most likely functions upstream of p38 mitogen activated protein kinase (MAPK) and stress-activated protein kinase/c-jun N-terminal kinase (SAPK/JNK) in osteoblasts and acts as a positive regulator [21] . Among the Rho family members, Rac1, a key component of cell movement and cell spreading, is crucial for generating actin-rich lamellipodial protrusions [22] . Rac1 executes its biological functions by activating downstream effectors, one of the best characterized of these being p21-activated kinase (PAK). It has been reported that Rac1 can activate p38 MAPK [23] as well as extracellular-regulated protein (ERK1/2) [24] .
One of the relevant downstream signaling cascades for mitogenic PLD signaling is the MAPK pathway, which includes the MAPK family's ERK1/2, p38 MAPK and SAPK/JNK. The signals that activate the MAPK pathways in response to PLD signal have been identified [25, 26] . Recently it has been reported that ERK1/2 induces the expression of Bcl-2 and Bcl-xL, and promotes the survival of human pancreatic tumor cells [27] . In addition, several MAPK family members including ERK1/2, p38 MAPK, and JNK are as kinases can phosphorylate Ser727 of the signal transducer and activator of transcription 3 (STAT3) [28] [29] [30] . STAT3 is responsible for the expression of several cytokines and growth factor receptors and is activated by phosphorylation at Tyr705, which induces its dimerization, nuclear translocation and DNA binding. In addition, activation of STAT3 results in the upregulation of various genes involved in the cell survival and proliferation such as Bcl-2, Bcl-xL, Mcl-1, cyclin D, and c-Myc.
In this study, we investigated the role of PLD in the Bcl-2 expression in HeLa cells. We found that PLD was important for upregulation of Bcl-2 and PA, an end product of PLD action also stimulated the expression of Bcl-2. Regulation of Bcl-2 expression occurred though three different pathways: the PLA 2 /G i /ERK1/2, RhoA/ROCK/ p38 MAPK and Rac1/p38 MAPK pathways. We also obtained evidence that STAT3 (Ser727) is a key transcription factor for the induction of Bcl-2 by PLD. Collectively, these observations suggest that PLD plays a critical role in enhancing Bcl-2 expression though PLA 2 /G i / ERK1/2, RhoA/ROCK/p38 MAPK, and Rac1/p38 MAPK pathways in HeLa cells.
Materials and methods

Materials
Fetal bovine serum (FBS), penicillin/streptomycin solution, and Dulbecco's modified Eagle's medium (DMEM) with L-glutamine and high glucose were purchased from WelGENE (Daegu, Korea). 1,2-Dipalmitoyl-sn-glycero-3-phosphate (DPPA), 1,2-Dioctanoly-snglycerol-3-phosphate sodium salt (PA) and oleoyl-sn-glycero-3-phosphate (LPA) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Antibodies used were as follows: Bcl-2 monoclonal antibody and GAPDH polyclonal antibody were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). PLD1 polyclonal antibody, ERK1/2 polyclonal antibody, p-ERK1/2 monoclonal antibody, p38 MAPK polyclonal antibody, p-p38 MAPK polyclonal antibody, STAT3 polyclonal antibody and p-STAT3 (Ser727) polyclonal antibody were obtained from Cell signaling (Beverly, MA, USA). Rac and Rho activation kits were from Upstate Biotechnology, Inc (Temecula, CA). Propranolol and mepacrine were purchased from Sigma-Aldrich (St. Louis, MO, USA). PD98059, SB203580, and Y-27632 were obtained from Calbiochem (San Diego, CA, USA).
Cell culture
HeLa cells were incubated for 2 days at 37°C in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% (v/v) heatinactivated FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin. Cells were grown at 37°C in a humidified CO 2 -controlled (5%) incubator, then washed with DMEM containing 0.1% (w/v) bovine serum albumin, 100 U/ml penicillin, and 100 μg/ml streptomycin (serumfree medium) and incubated in serum-free medium at 37°C for 18 h before treatment.
Transient transfection and infection of HeLa cells
For transient infection, retroviral constructs of vector-control, PLD1 wild type (wt), and PLD2 wild type (wt) were added to HeLa cells. After overnight culture, the virus containing medium was replaced with fresh complete medium.
For transfection experiments, 5 μg each of Cdc42 dominant-negative (N17), RhoA dominant-negative (N19), Rac1dominant-negative (N17), pMSCV-HA-IRES-CL-EGFP and pMSCV-HA-STAT3-IRES-CL-EGFP plasmid were transiently transfected into HeLa cells, using Lipofectamine™ 2000 reagents (Invitrogen, CA, USA). After 48 h of transfection, the cells were serum-starved for 18 h and then treated with PA.
Western blot analysis
Cells were first lysed in 20 mM Tris, pH 7.5, containing 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 2.5 mM sodium pyrophosphate, 1% Triton X-100, 1 mM phenylmethylsulfonyl-fluoride, and 1 mM Na3VO 4 . Protein lysates ranging from 20 to 30 μg were subsequently loaded onto SDS-polyacrylamide gels (10-12%), electrophoresed, and transferred to nitrocellulose membrane (Amersham Biosciences). After being blocked with 5% dried skim milk for 1 h, the membrane was incubated with primary antibodies. Blots were further incubated with horseradish peroxidase-conjugated secondary antibody (1:2000, New England Biolabs, Beverly, MA), and specific bands were detected with ECL (Ab FRONTIER).
Luciferase assay
The Bcl-2 promoter construct was provided by Gu Kong (Hanyang University, Seoul, Korea). Cells were cotransfected with either the control vector (pCAT-Luc) and pCMV-β-gal or Bcl-2 promoter (Bcl-2 pCAT-Luc) and pCMV-β-gal with PLD1and PLD2. At 48 h after the transfection, cells were stimulated with PA for 3 h. Depending on the reporter construct used the level of expression from the target was analyzed by Firefly luciferase assay. Luciferase activities, read with a Luminometer (Berthold, USA) were normalized to β-galactosidase activity measured in the corresponding cell extracts.
Chromatin immunoprecipitation (CHIP) assay
Nuclear isolation, cross-linking, and chromatin immunoprecipitation assays (CHIP) on PA-stimulated HeLa cells were performed as described previously [31] . Precipitated DNA fragments were analyzed by PCR using primers against relevant human Bcl-2 promoters. Primers used were as follows: STAT3 (1), sense, 5′-CTTCATTTATC-CAGCAGCTT-3′ and antisense, 5′-GAGGGGACGATGAAGGAG-3′, PCR conditions comprised an initial polymerase activation step at 94°C for 5 min, followed by denaturation for 33 cycles at 94°C for 30 s, annealing at 56°C for 30 s and extension at 72°C for 30 s. For STAT3 (2), sense,5′-CTCTTGAGATCTCCGGT-TG-3′ and antisense, 5′-GGGGA-GAGGGA-GTAAAAAT-3′. The PCR conditions comprised an initial polymerase activation step at 94°C for 5 min, followed by denaturation for 28 cycles at 94°C for 30 s, annealing at 56°C for 30 s and extension at 72°C for 30 s.
Rac1 and RhoA activity assay
For pull down assays, HeLa cells were lysed in 125 mM HEPES, pH 7.5, containing 750 mM NaCl, 5 mM EDTA, 5% lgepal CA-630, 50 mM MgCl 2 , 10% glycerol 10 μg/ml aprotinine and 10 μg/ml leupeptin. Equal amounts of total protein from clarified lysates were incubated with GST-PBD (p21-binding domain of human PAK-1) or GST-RBD (Rho binding domain of rhotekin) to precipitate GTP-bound Rac1 and GTP-bound RhoA, respectively, according to the manufacturer's instructions (Upstate Biotechnology). Precipitated GTP-bound Rac1 and RhoA were resolved by a 12% SDS-PAGE and immunoblotted with monoclonal antibodies specific for Rac1 (1 μg/ml; Upstate Biotechnology) or RhoA (3 μg/ml; Upstate-Biotechnology). Six percent of each cell lysate was also resolved by 12% SDS-PAGE and immunoblotted to measure the total amounts of Rac1 and RhoA.
Small interfering RNA
Human STAT3 siRNA was purchased from Ambion (Austin, TX, USA), and Human RhoA and Rac1 were purchased from Bioneer (Seoul, Korea). A negative control was carried out with Negative Control siRNA #2 (from Ambion). The oligonucleotide siRNAs were transfected using siPORTTM NeoFX (Ambion) reagent according to the manufacturer's instructions. At the indicated intervals following transfection, cell lysates were assayed for gene silencing by Western blotting.
Statistical analysis
All experiments were performed at least in triplicate, and results are expressed as means ± SD. The statistical significance of differences was assessed by an unpaired t-test.
Results
PLD overexpression increases Bcl-2 expression in HeLa cells
To investigate the role of PLD in the Bcl-2 expression in HeLa cells, we first tested whether Bcl-2 expression was stimulated by infection of vectors containing wild-type PLD1 or PLD2. Overexpression of the PLD isozymes indeed enhanced the expression of Bcl-2 as well as the activity of its promoter ( Fig. 1A and B) . Moreover, PA, the end product of PLD, increased expression of Bcl-2 ( Fig. 1C ). As shown in Fig. 1D , PA also significantly increased Bcl-2 promoter activity (p b 0.01). These results indicate that PLD plays an essential role in the expression of Bcl-2 in HeLa cells.
PA is involved in upregulation of Bcl-2 expression in HeLa cells
In general, PLD exerts its effects by generating PA. PA is degraded to diacylglycerol by phospholyhydrolase (PAP) or to LPA/arachidonic acid (AA) by PLA 2 . Therefore, to determine whether PA itself regulates Bcl-2 expression, we pretreated cells with mepacrine (a PLA 2 inhibitor) or propranolol (a PAP inhibitor) for 1 h prior to treatment with PA for 3 h. As shown in Fig. 2A , pretreatment with mepacrine reduced PAinduced Bcl-2 expression, whereas pretreatment with propranolol had no effect on Bcl-2 expression, suggesting that a PLA 2 metabolite of PA is involved in the expression of Bcl-2. PLA 2 converts PA into AA and LPA. To confirm which of PA metabolites are involved in the increased Bcl-2 expression, we treated DPPA which contains palmitic acid instead of AA, for 1 h. Treatment with DPPA resulted in increased Bcl-2 expression (Fig. 2B) . Moreover, when the cells were treated with LPA for the indicated time, Bcl-2 expression was also increased (Fig. 2C) . These results suggest that LPA, as a metabolite of PA by PLA 2 has great importance in the upregulation of Bcl-2.
3.3. The PLA 2 /Gi/ERK1/2, RhoA/ROCK/p38 MAPK, and Rac1/p38 MAPK pathways are involved in expression of Bcl-2 by PLD in HeLa cells PLD activates the MAPK cascade through PA-mediated translocation of Raf-1 to cellular membranes [26] . In addition, MAP kinase is a well-known target of PA. To investigate whether the MAP kinase cascade is involved in PLD-mediated signaling events, we infected HeLa cells with vector control, and vector expressing wild-type PLD1 or wild-type PLD2. As, shown Fig. 3A , overexpression of PLD1 or PLD2, increased activation of ERK1/2. Treatment with PA also increased ERK1/2 phosphorylation with a maximum effect after 15 min (Fig. 3B ). In addition, to determine whether PLA 2 is involved in the PA-induced ERK1/2 activation, cells were pretreated with the PLA 2 inhibitor, mepacrine. Pretreatment with mepacrine suppressed PAinduced ERK1/2 activation (Fig. 3C) , indicating that ERK1/2 function at the downstream of PLA 2 .
LPA has been described as a PLD activator in several different cells types, including fibroblasts, endothelial cells, epithelial cells, and prostate cancer cells [32] [33] [34] [35] [36] . It is coupled to a variety of downstream signaling cascades through different classes of G proteins including G i , G q , and G 12/13 [37] . It induces various biological effects through both pertussis toxin (PTX)-sensitive (Gi) and -insensitive (G 12/13 , G q ) G-proteins. Moreover, MAPKs, including ERK1/2, and p38 MAPK, have been shown to be activated downstream of GPCR. As shown in Fig. 3D , LPA-induced ERK1/2 phosphorylation and Bcl-2 expression were inhibited by treatment with PTX, which demonstrates that activation of ERK1/2 and upregulation of Bcl-2 expression by LPA are mediated through G i -protein activation. Therefore, we further examined whether another MAPKs, p38 MAPK, is also involved in PLD-mediating signaling in HeLa cells. To confirm the activation of p38 MAPK by PLD, we first infected HeLa cells with PLD isozymes. Activation of p38 MAPK was increased by overexpression of PLD or treatment of PA in a time dependent manner (Fig. 4A and B) . Next, to find out whether PLA 2 is involved in the PA-induced p38 MAPK activation, effect of mepacrine, the PLA 2 inhibitor, was measured. This did not affect PA-induced p38 MAPK phosphorylation (Fig. 4C) . To confirm LPA is not required for the PA-induced p38 MAPK activation, we treated LPA for 15 min to the cells. Treatment with LPA has no effect on p38 MAPK activation (Fig. 4D) . These results indicate that PLA 2 /Gi pathway is not involved in the PA-induced p38 MAPK phosphorylation. Small GTP-binding proteins including Rho, Cdc42, and, Rac1 have been implicated in cellular responses such as apoptosis, migration, proliferation, and gene expression. The MAPKs including ERK1/2, p38 MAPK, and SAPK/JNK act downstream of these small GTP-binding proteins [38] . In addition, activation of Rho can prevent apoptosis by increasing expression of the Bcl-2 and Bcl-xL [39, 40] . To investigate possible roles of Cdc42, RhoA, and Rac1 in PLD-mediated Bcl-2 expression, we transfected HeLa cells with dominant-negative mutants of each of these factors and then the cells were treated with PA for 3 h. As shown Fig. 4E , PA-induced increase of p38 MAPK phosphorylation and Bcl-2 expression were reduced in cells transfected with dominant-negative mutants of RhoA and Rac1, but not that of Cdc42. However, ERK1/2 phosphorylation was unaffected by any of the dominant negative small GTP-binding proteins (data not shown). Also, we confirmed the effect of RhoA and Rac1 on Bcl-2 expression by introducing RhoA and Rac1 specific siRNAs. PA-induced increase of p38 MAPK phosphorylation and Bcl-2 expression were completely abolished with treatment of RhoA and Rac1 siRNAs (Fig. 4F) . These findings demonstrated that RhoA and Rac1 are required for both of the activation of p38 MAPK and Bcl-2 expression. To assess the effect of PA on activations of RhoA and Rac1, we measured the intracellular concentrations of GTP-bound RhoA and Rac1 in the presence or absence of PA and LPA, as described in Section 2. PA increased the GTP-bound forms of both factors, but LPA did not ( Fig. 4G and H) . To determine whether the Rho-kinase, ROCK, a downstream target of Rho, was involved in the PA-induced increase of p38 MAPK phosphorylation and Bcl-2 expression, we treated cells for 1 h with Y27632, a specific inhibitor of Rho-kinase and found that Y27632 reduced p38 MAPK phosphorylation and Bcl-2 expression induced by PA treatment (Fig. 4I) . Taken together, these results suggest that PA activates RhoA and Rac1, which may in turn enhance of Bcl-2 expression via a p38 MAPK-mediated pathway.
PA-induced Bcl-2 expression is dependent on the activation of ERK1/2 and p38 MAPK in HeLa cells
As shown in Figs. 3 and 4 , ERK1/2 and p38 MAPK are activated by overexpression of PLD isozymes in HeLa cells. As expected, the level of phosphorylated ERK1/2 and p38 MAPK was increased after treatment of PA. To determine whether ERK1/2 and p38MAPK are actually involved in the Bcl-2 expression induced by PA, we used the MEK inhibitor, PD98059 and p38MAPK inhibitor, SB203580, to block activation of ERK1/2 and p38MAPK, respectively. As shown in Fig. 5 , when the cells were pretreated with either PD98059 or SB203580, PA-induced Bcl-2 expression was reduced, but not completely. When the cells were pretreated with both PD98059 and SB203580 at the same time, PA-induced Bcl-2 expression was completely blocked, demonstrating that PA independently induces Bcl-2 expression through both the ERK1/2 and P38 MAPK pathways.
The activation of STAT3 is involved in Bcl-2 expression by PLD in HeLa cells
STAT3 is a key signaling molecule for many cytokines, and it is activated by phosphorylation of Ser 727 and/or Tyr 705 residues which are targets of MAPKs [41, 42] . Therefore, we examined STAT3 phosphorylation after infection with constructs expressing the PLD isozymes. Overexpression of PLD isozymes increased Ser727 phosphorylation of STAT3 (Fig. 6A) . PA, also increased STAT3 (Ser 727) phosphorylation in a timedependent manner (Fig. 6B) . Phosphorylation of Tyr705 residue of STAT3 was not affected by overexpression of PLD isozymes or PA treatment (data not shown). PA-induced STAT3 (Ser 727) phosphorylation was inhibited by pretreatment with mepacrine or PTX ( Fig. 6C and D) , as well as by transfection with the dominant-negative mutants of RhoA or Rac1 (data not shown). As shown in Fig. 6E , PD98059 and SB203580 partially blocked PA-induced STAT3 (Ser727) phosphorylation, respectively, whereas treatment with both of PD98059 and SB 203580 at the same time completely blocked PA-induced STAT3 phosphorylation, indicating that PA-induced STAT3 phosphorylation occurs through ERK1/2 and p38MAPK pathways independently. Next, to determine whether the activated form of STAT3 observed above can bind to the Bcl-2 promoter, we looked for STAT3-binding sites in the Bcl-2 promoter region. We identified two putative STAT3-binding sites in the Bcl-2 promoter (STAT3I: −1022 to −1002, STAT3Π: −791 to −699). We determined whether STAT3 can directly bind to the Bcl-2 promoter by performing a chromatin immunoprecipitation assay. As expected, the Bcl-2 genomic fragments captured by anti-STAT3 (Ser 727) were detected by PCR. Specifically, the binding of STAT3 to the Bcl-2 promoter was increased by treatment with PA for 15 min (Fig. 6F) , suggesting that PA-induced STAT3 activation is essential for binding to the Bcl-2 promoter and increasing Bcl-2 expression. Furthermore, to investigate whether PLA 2 /G i , RhoA, and Rac1 related pathways are important for the binding of STAT3 to Bcl-2 promoter, we examined the effects of PTX, RhoA or Rac1 siRNA transfection. As shown in Fig. 6G , PTX completely abolished the binding of STAT3 to the Bcl-2 promoter induced by PA. Also, knockdown of RhoA or Rac1 Fig. 5 . Activations of the ERK1/2 and p38 MAPK are involved in PA-induced Bcl-2 expression in HeLa cells. HeLa cells were pretreated with 50 μM PD98059 and/or 50 μM SB203580 for 1 h and then stimulated with 50 μM PA for 15 min (for p-ERK1/2, p-p38 MAPK) and 3 h (for Bcl-2). Expression levels of ERK1/2, p-ERK1/2, p38 MAPK, p-p38MAPK and Bcl-2 were determined by Western blot analysis. Bands were quantified using Image J software (NIH-http//rsb.info.nih.gov/ij/).
showed disappearance of STAT3 binding to the Bcl-2 promoter induced by PA. Taken together, these data demonstrated that PLD plays an important role in STAT3 activation via the PLA 2 /G i /ERK1/2, RhoA/ROCK/ p38 MAPK, and Rac1/p38 MAPK pathways.
Overexpression or knockdown of STAT3 regulates PA-induced Bcl-2 expression
Finally, we investigated the effect of STAT3 activation on PA-induced Bcl-2 expression in HeLa cells. HeLa cells were transiently transfected with pMSCV-HA-STAT3-IRES-CL-EGFP or pMSCV-HA-IRES-CL-EGFP as a control. As shown in Fig. 7A , overexpression of STAT3 by transient transfection with pMSCV-HA-STAT3-IRES-CL EGFP led to more than a two-fold increase in Bcl-2 expression in the absence of PA compared to the controls. Furthermore, knockdown of STAT3 using STAT3 siRNA decreased PA-induced Bcl-2 expression compared to control siRNA (Fig. 7B) , scramble siRNA was transfected as a control. These results suggest that Bcl-2 expression is regulated by STAT3 transcriptional activity in HeLa cells.
Discussion
PLD is a crucial enzyme providing defense against apoptosis induced by various effectors including hydrogen-peroxide, glutamate and Fas/CD95 agonist [43] [44] [45] [46] . PLD expression and activity have been implicated in the expression of anti-apoptotic proteins via a number of signaling pathway. Recently, a close relationship between activation of PLD and expression of Bcl-2 has been reported in stomach cells and A20 cells [11, 12] . However, the precise mechanism of Bcl-2 upregulation by PLD remained unclear. In the present study, we showed that In general, PLD is a key signaling molecule in cell physiology due to generation of PA. PA is converted to DAG by PAP, and hydrolyzed to AA and LPA by PLA 2 . In our data, propranolol had no effect on PA-induced Bcl-2 expression, whereas mepacrine significantly suppressed PAinduced Bcl-2 expression, suggesting that PLA 2 , but not PAP, is involved in the increased expression of Bcl-2 in HeLa cells. Consistent with this observation, several studies have shown that PLD and PLA 2 are involved in increasing Bcl-2 expression via LPA synthesis [47] [48] [49] [50] . To rule out involvement of AA another PLA 2 product, we treated cells with DPPA, which has two palmitic acids instead of AA. We found that DPPA increased the expression of Bcl-2, suggesting that LPA, not AA, is a key molecule involved in Bcl-2 expression. LPA exerts diverse cellular effects by activating specific G protein-coupled receptors (GPCRs). Six LPA-specific mammalian GPCRs, LPA [1] [2] [3] [4] [5] [6] , have been identified. LPA [1] [2] [3] are members of the endothelial differentiation gene (EDG) family, the other members, LPA [4] [5] [6] , which are also similar to members of the Edg family, were identified only recently and less is known about them [51] [52] [53] [54] [55] [56] . We have found that LPA 2 , LPA 5 , and LPA 6 are expressed in HeLa cells, whereas LPA 1 , LPA 3 , and LPA 4 are not detectible (data not shown). G-proteins such as G i / o , G q / 11 , and G 12 / 13 can be activated by stimulated GPCR S [57, 58] . Of these G-proteins, G i/o protein is the most promising candidate for mediating the activation of tyrosine kinases and MAP kinases by LPA [59] . MAPKs including ERK1/2 and p38 MAPK are downstream molecules of GPCR. Therefore, we tried to determine whether the ERK1/2 signaling pathway is involved in the PLD mediated regulation of Bcl-2, and found that overexpression of PLD isozymes or PA treatment increased phosphorylation of ERK1/2. To this end, we found that mepacrine, PLA 2 inhibitor, blocked PA-induced ERK1/2 phosphorylation, and PTX, a G i / o inhibitor, reduced both LPAinduced ERK1/2 activation and Bcl-2 expression suggesting that PLD activates ERK1/2 and induces Bcl-2 expression through a PLA 2 /G i pathway. However, PTX did not completely block the increase of Bcl-2 expression, which implies that there are other pathways for PLD mediated Bcl-2 expression. Accordingly, we examined p38 MAPK as another molecule downstream of GPCR. Phosphorylation of p38 MAPK was not affected by mepacrine, even though it was activated by overexpression of PLD isozymes and PA treatment, suggesting that it is not involved in the PLA 2 /G i pathway. Rho-related GTPases can regulate gene expression by activating MAP kinase cascades [60] , and Rho family proteins have been shown to differentially affect different members of the Bcl-2 family. For examples, RhoA/ROCK suppresses the pro-apoptotic protein Bax and enhances the anti-apoptotic proteins Bcl-2 and Bcl-xl, whereas activation of the Rac1/Cdc42/PAK pathway inhibits pro-apoptotic proteins including, Bax, Bim, and Bad, and stimulates Bcl-2 and Bcl-xl expression [61] [62] [63] . In the present study, we found that PA stimulated activation of Rac1 and RhoA and that inhibition of Rac1, RhoA or the RhoA downstream effecter, ROCK, blocked both PA-induced p38 activation and Bcl-2 expression. This showed that PA-induced p38 MAPK activation was dependent on two pathways: RhoA/ROCK and Rac1. Interestingly, we found that PA-induced Bcl-2 expression was not completely blocked by either PD98059 or SB203580; however when cells were treated with both inhibitors at same time, PA-induced Bcl-2 expression was completely blocked, indicating that PA-induced Bcl-2 expression is independently regulated by ERK1/2 and p38 MAPK, respectively. Thus, we were able to conclude that the PLA 2 /G i /ERK1/2, RhoA/ROCK-/p38 MAPK and Rac1/p38 MAPK pathways all participate in PA-induced Bcl-2 expression in HeLa cells.
In general, STAT3 is a cytoplasmic transcription factor that is involved in cell growth, cell differentiation, cell survival, and the inflammatory response [64, 65] . It is activated by the MAPK family including ERK1/2, p38MAPK and SAPK/JNK in different cell lines [41, 42] and, activation of STAT3 regulates Bcl-2 expression [66, 67] . We previously showed that STAT3 phosphorylation regulates Bcl-2 expression in response to ERK1/2 activation [68] . In the present study, we found that overexpression of PLD isozymes or PA treatment increased Ser727 phosphorylation of STAT3, but not its Tyr705 phosphorylation. Pretreatment with mepacrine, PTX, PD98059 or SB203580 blocked the phosphorylation of STAT3 (Ser727) and DN-RhoA and DN-Rac1 inhibited the PA-induced STAT3 (Ser727) phosphorylation (data not shown).
Bcl-2 expression is regulated by several transcription factors, including Sp-1, NF-кB, CREB, AP-1 and STAT3. Recent studies show that activated STAT3 can bind directly to a sis inducible element in the murine Mcl-1 promoter and increase Bcl-2 and Bcl-xL promoter activity [69, 70] . In the present study, we identified two functional STAT3 binding sites in the Bcl-2 promoter region and found that STAT3 (Ser727) upregulated Bcl-2 expression via direct interaction with the Bcl-2 promoter. PA-induced Bcl-2 expression was reduced by STAT3 knockdown using siRNA. However, another candidate, NF-кB, was not interacted with the Bcl-2 promoter in the presence of PA (data not shown). These results all indicate that PLD increases Bcl-2 expression by activating STAT3 (Ser 727) in HeLa cells.
In conclusion, our present study provides evidences that PLD is a critical molecule in the activation of PLA 2 /G i /ERK1/2, RhoA/ROCK/ p38 MAPK and Rac1/p38 MAPK pathways, respectively: These three different pathways all appear to participate in the activation of STAT3 (Ser727) resulting in increased expression of Bcl-2 in HeLa cells (Fig. 8) .
